192 related articles for article (PubMed ID: 32586581)
21. Follicular lymphoma: clinical features and treatment.
Tan D; Horning SJ
Hematol Oncol Clin North Am; 2008 Oct; 22(5):863-82, viii. PubMed ID: 18954741
[TBL] [Abstract][Full Text] [Related]
22. Epidemiology of Follicular Lymphoma.
Cerhan JR
Hematol Oncol Clin North Am; 2020 Aug; 34(4):631-646. PubMed ID: 32586570
[TBL] [Abstract][Full Text] [Related]
23. Transformation of follicular lymphoma - Why does it happen and can it be prevented?
Link BK
Best Pract Res Clin Haematol; 2018 Mar; 31(1):49-56. PubMed ID: 29452666
[TBL] [Abstract][Full Text] [Related]
24. Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL).
Rusconi C; Anastasia A; Chiarenza A; Marcheselli L; Cavallo F; Rattotti S; Botto B; Ferrari A; Nassi L; Pagani C; Meli E; Arcaini L; Federico M; Rossi G;
Br J Haematol; 2019 May; 185(4):713-717. PubMed ID: 30793297
[TBL] [Abstract][Full Text] [Related]
25. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.
Plancarte F; López-Guillermo A; Arenillas L; Montoto S; Giné E; Muntañola A; Ferrer A; Villamor N; Bosch F; Colomo L; Balaguer O; Campo E; Montserrat E
Eur J Haematol; 2006 Jan; 76(1):58-63. PubMed ID: 16343272
[TBL] [Abstract][Full Text] [Related]
26. Histologic transformation of follicular lymphoma: pathologists' viewpoint.
Maeshima AM
J Clin Exp Hematop; 2023; 63(1):12-18. PubMed ID: 36990772
[TBL] [Abstract][Full Text] [Related]
27. Individualized management of follicular lymphoma.
Bai B; Huang HQ
Chin Clin Oncol; 2015 Mar; 4(1):7. PubMed ID: 25841714
[TBL] [Abstract][Full Text] [Related]
28. Transformation in Low-grade B-cell Neoplasms.
Montgomery ND; Mathews SP
Surg Pathol Clin; 2016 Mar; 9(1):79-92. PubMed ID: 26940269
[TBL] [Abstract][Full Text] [Related]
29. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients.
Bastion Y; Sebban C; Berger F; Felman P; Salles G; Dumontet C; Bryon PA; Coiffier B
J Clin Oncol; 1997 Apr; 15(4):1587-94. PubMed ID: 9193357
[TBL] [Abstract][Full Text] [Related]
30. How I manage patients with follicular lymphoma.
Casulo C
Br J Haematol; 2019 Aug; 186(4):513-523. PubMed ID: 31173345
[TBL] [Abstract][Full Text] [Related]
31. Follicular lymphoma: evolving therapeutic strategies.
Kahl BS; Yang DT
Blood; 2016 Apr; 127(17):2055-63. PubMed ID: 26989204
[TBL] [Abstract][Full Text] [Related]
32. The Biological Basis of Histologic Transformation.
Kumar EA; Okosun J; Fitzgibbon J
Hematol Oncol Clin North Am; 2020 Aug; 34(4):771-784. PubMed ID: 32586580
[TBL] [Abstract][Full Text] [Related]
33. Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.
Sarkozy C; Trneny M; Xerri L; Wickham N; Feugier P; Leppa S; Brice P; Soubeyran P; Gomes Da Silva M; Mounier C; Offner F; Dupuis J; Caballero D; Canioni D; Paula M; Delarue R; Zachee P; Seymour J; Salles G; Tilly H
J Clin Oncol; 2016 Aug; 34(22):2575-82. PubMed ID: 27298402
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors in follicular lymphoma.
Relander T; Johnson NA; Farinha P; Connors JM; Sehn LH; Gascoyne RD
J Clin Oncol; 2010 Jun; 28(17):2902-13. PubMed ID: 20385990
[TBL] [Abstract][Full Text] [Related]
35. Is watch and wait still acceptable for patients with low-grade follicular lymphoma?
Armitage JO; Longo DL
Blood; 2016 Jun; 127(23):2804-8. PubMed ID: 26994147
[TBL] [Abstract][Full Text] [Related]
36. Transformation of indolent B-cell lymphomas.
Montoto S; Fitzgibbon J
J Clin Oncol; 2011 May; 29(14):1827-34. PubMed ID: 21483014
[TBL] [Abstract][Full Text] [Related]
37. Follicular Lymphoma: Redefining Prognosis, Current Treatment Options, and Unmet Needs.
Welaya K; Casulo C
Hematol Oncol Clin North Am; 2019 Aug; 33(4):627-638. PubMed ID: 31229159
[TBL] [Abstract][Full Text] [Related]
38. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
Alonso-Álvarez S; Magnano L; Alcoceba M; Andrade-Campos M; Espinosa-Lara N; Rodríguez G; Mercadal S; Carro I; Sancho JM; Moreno M; Salar A; García-Pallarols F; Arranz R; Cannata J; Terol MJ; Teruel AI; Rodríguez A; Jiménez-Ubieto A; González de Villambrosia S; Bello JL; López L; Monsalvo S; Novelli S; de Cabo E; Infante MS; Pardal E; García-Álvarez M; Delgado J; González M; Martín A; López-Guillermo A; Caballero MD
Br J Haematol; 2017 Sep; 178(5):699-708. PubMed ID: 28782811
[TBL] [Abstract][Full Text] [Related]
39. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
[TBL] [Abstract][Full Text] [Related]
40. Prolymphocytoid transformation of follicular lymphoma with coexpression of CD5 and CD10.
Lau SK; Weiss LM; Zhang Y; Huang Q
Leuk Lymphoma; 2006 Mar; 47(3):541-7. PubMed ID: 16396778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]